Total value in 2019: $943.57M

 

Company Partner Amount ($M) Details Date

November - $165M

Alkermes plc (Dublin) Biogen Inc. (Cambridge, Mass.) $150.00 Alkermes received a $150M milestone payment from Biogen triggered by the recent FDA approval of Vumerity (diroximel fumarate) for relapsing forms of multiple sclerosis 11/13/19
Peptidream Inc. (Kanagawa, Japan) Merck & Co. Inc. (Kenilworth, N.J.) N/A Peptidream reached a milestone in its collaboration with Merck by identifying candidates meeting predefined criteria triggering an undisclosed payment 11/27/19
PTC Therapeutics Inc. (South Plainfield, N.J.) Roche Holding AG (Basel, Switzerland) $15.00 NDA filing acceptance by the FDA for the survival motor neuron-2 splicing modifier risdiplam (RG-7916) to treat spinal muscular atrophy triggered a $15M milestone payment to PTC Therapeutics from Roche Holding 11/25/19

No Comments